Key facts
- Camascope’s last known valuation is $20.5M (Jan 2025).
- It has raised $9.4M; the latest was Later Stage VC ($6.5M) in Jan 2025.
- Notable investors include David Stevens, Dharamveer Basude, Henning Behre, Hetal Shah, Lonepiper — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Camascope
- ·The full record, as it builds
Funding rounds
No funding rounds for Camascope are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Camascope
Developer of an electronic medication administration record platform designed to connect different healthcare systems and stakeholders. The company provides a remote patient monitoring platform that offers video consultations, monitoring kits, personalized patient care and patient onboarding and also sends medicine order requests electronically, enabling patients to get access to medications at the doorstep to improve medicine compliance and reduce errors by alerting care home staff to potentially missed medicines.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2015
- Employees
- 69
- Website
- camascope.com/
- Ownership
- Privately Held (backing)
Camascope doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Camascope shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Camascope in its N-PORT filings yet. We sweep new filings monthly.